晚期肠癌因化疗优化选择.pptVIP

NCCN指南明确指出维持治疗的价值 SFDA未批准希罗达在结直肠癌中联合化疗的适应症 维持治疗的目标 Waddell T, Gollins S, Soe W, et al. Phase Ⅱ study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study [J]. Cancer Chemotherapy and Pharmacology, 2010, 5(67): 1111 - 7. 主要终点 PFS 次要终点 有效率 顺应性 总生存时间 XelQuali研究: XELOX序贯卡培他滨单药治疗 SFDA未批准希罗达在结直肠癌中联合化疗的适应症 维持治疗让晚期结直肠癌患者进一步获益 Waddell T, Gollins S,Soe W, et al. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. Cancer